Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Plaque, Atherosclerotic | 93 | 2024 | 1533 | 6.700 |
Why?
|
Tomography, Optical Coherence | 104 | 2024 | 2917 | 4.070 |
Why?
|
Coronary Vessels | 78 | 2024 | 3096 | 3.720 |
Why?
|
Acute Coronary Syndrome | 59 | 2024 | 2190 | 3.560 |
Why?
|
Coronary Artery Disease | 76 | 2024 | 6403 | 3.020 |
Why?
|
Teriparatide | 20 | 2022 | 227 | 2.250 |
Why?
|
Bone Density | 56 | 2024 | 3551 | 2.120 |
Why?
|
Coronary Angiography | 79 | 2024 | 4471 | 2.010 |
Why?
|
Bone Density Conservation Agents | 22 | 2024 | 795 | 1.940 |
Why?
|
Osteoporosis, Postmenopausal | 14 | 2024 | 396 | 1.890 |
Why?
|
Coronary Thrombosis | 10 | 2021 | 440 | 1.070 |
Why?
|
Ultrasonography, Interventional | 19 | 2023 | 1496 | 0.930 |
Why?
|
Amenorrhea | 10 | 2018 | 483 | 0.920 |
Why?
|
Students | 13 | 2009 | 1741 | 0.750 |
Why?
|
Predictive Value of Tests | 51 | 2024 | 15266 | 0.740 |
Why?
|
Growth Hormone-Releasing Hormone | 5 | 2024 | 128 | 0.730 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2020 | 3245 | 0.730 |
Why?
|
Bone and Bones | 15 | 2024 | 2568 | 0.730 |
Why?
|
Alendronate | 8 | 2024 | 175 | 0.710 |
Why?
|
Testosterone | 17 | 2020 | 2472 | 0.690 |
Why?
|
Middle Aged | 246 | 2024 | 220895 | 0.690 |
Why?
|
Universities | 9 | 2009 | 993 | 0.680 |
Why?
|
Athletes | 11 | 2019 | 1137 | 0.660 |
Why?
|
Female | 309 | 2024 | 392644 | 0.660 |
Why?
|
Body Composition | 21 | 2023 | 2426 | 0.630 |
Why?
|
Humans | 400 | 2024 | 761504 | 0.590 |
Why?
|
Gonadotropin-Releasing Hormone | 11 | 2021 | 1148 | 0.570 |
Why?
|
Lipids | 20 | 2024 | 3341 | 0.560 |
Why?
|
Drug-Eluting Stents | 8 | 2017 | 681 | 0.560 |
Why?
|
Bone Remodeling | 12 | 2024 | 581 | 0.560 |
Why?
|
Rupture, Spontaneous | 14 | 2024 | 362 | 0.550 |
Why?
|
Male | 248 | 2024 | 360804 | 0.550 |
Why?
|
Aged | 162 | 2024 | 169289 | 0.530 |
Why?
|
Myocardial Infarction | 18 | 2024 | 11460 | 0.530 |
Why?
|
Atherosclerosis | 12 | 2024 | 3408 | 0.520 |
Why?
|
HIV Infections | 27 | 2024 | 17351 | 0.520 |
Why?
|
Ovarian Neoplasms | 21 | 2020 | 4876 | 0.510 |
Why?
|
Alcohol Drinking | 10 | 2009 | 4028 | 0.510 |
Why?
|
Coronary Stenosis | 7 | 2021 | 794 | 0.510 |
Why?
|
Anorexia Nervosa | 8 | 2018 | 1361 | 0.490 |
Why?
|
Absorptiometry, Photon | 22 | 2024 | 1738 | 0.490 |
Why?
|
Chest Pain | 8 | 2015 | 1091 | 0.480 |
Why?
|
Goserelin | 4 | 2020 | 126 | 0.470 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 6 | 2017 | 698 | 0.460 |
Why?
|
Radius | 9 | 2024 | 441 | 0.440 |
Why?
|
Adult | 172 | 2024 | 221177 | 0.440 |
Why?
|
Coronary Circulation | 6 | 2021 | 1569 | 0.430 |
Why?
|
Postmenopause | 8 | 2024 | 2513 | 0.430 |
Why?
|
Estrone | 3 | 2023 | 234 | 0.410 |
Why?
|
Mixed Tumor, Mullerian | 6 | 2009 | 55 | 0.400 |
Why?
|
Neointima | 6 | 2015 | 133 | 0.390 |
Why?
|
Fibroblast Growth Factors | 7 | 2015 | 867 | 0.380 |
Why?
|
Treatment Outcome | 76 | 2024 | 64680 | 0.380 |
Why?
|
Osteoporosis | 10 | 2017 | 1606 | 0.370 |
Why?
|
Estradiol | 9 | 2019 | 1937 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 11742 | 0.360 |
Why?
|
Tibia | 8 | 2024 | 1070 | 0.350 |
Why?
|
Nerve Fibers | 3 | 2024 | 708 | 0.350 |
Why?
|
Adipose Tissue | 9 | 2024 | 3312 | 0.350 |
Why?
|
Fibrinolytic Agents | 6 | 2021 | 2084 | 0.330 |
Why?
|
Alcoholic Intoxication | 3 | 2009 | 174 | 0.320 |
Why?
|
Glaucoma, Open-Angle | 3 | 2024 | 738 | 0.320 |
Why?
|
Kidney Transplantation | 5 | 2023 | 4234 | 0.320 |
Why?
|
Genital Neoplasms, Female | 5 | 2022 | 532 | 0.320 |
Why?
|
Retrospective Studies | 66 | 2024 | 80636 | 0.320 |
Why?
|
Arteritis | 2 | 2024 | 158 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 4 | 2019 | 1208 | 0.310 |
Why?
|
Oligomenorrhea | 2 | 2019 | 42 | 0.310 |
Why?
|
Staphylococcal Infections | 5 | 2016 | 1408 | 0.310 |
Why?
|
Oxytocin | 2 | 2023 | 402 | 0.300 |
Why?
|
Bone Resorption | 4 | 2019 | 723 | 0.300 |
Why?
|
Retinal Ganglion Cells | 3 | 2024 | 811 | 0.300 |
Why?
|
Fractures, Bone | 7 | 2023 | 2046 | 0.300 |
Why?
|
Stents | 12 | 2022 | 3179 | 0.290 |
Why?
|
Mammary Arteries | 2 | 2024 | 81 | 0.290 |
Why?
|
Young Adult | 52 | 2024 | 59243 | 0.290 |
Why?
|
Cross Infection | 6 | 2018 | 1422 | 0.280 |
Why?
|
Calcinosis | 4 | 2022 | 1469 | 0.280 |
Why?
|
Time Factors | 45 | 2024 | 39967 | 0.280 |
Why?
|
Adolescent | 68 | 2024 | 88319 | 0.280 |
Why?
|
Coronary Restenosis | 3 | 2015 | 396 | 0.280 |
Why?
|
Sirolimus | 6 | 2022 | 1533 | 0.280 |
Why?
|
Libido | 2 | 2020 | 119 | 0.280 |
Why?
|
Human Growth Hormone | 4 | 2020 | 642 | 0.280 |
Why?
|
Drug Administration Schedule | 13 | 2024 | 4853 | 0.280 |
Why?
|
Adiposity | 5 | 2020 | 1878 | 0.270 |
Why?
|
Starvation | 2 | 2018 | 142 | 0.270 |
Why?
|
Endothelium, Vascular | 4 | 2021 | 4431 | 0.270 |
Why?
|
Transplantation Chimera | 2 | 2019 | 594 | 0.270 |
Why?
|
Transplantation Tolerance | 3 | 2023 | 605 | 0.270 |
Why?
|
Follow-Up Studies | 36 | 2024 | 39106 | 0.260 |
Why?
|
Optic Nerve Diseases | 2 | 2024 | 342 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2023 | 9280 | 0.260 |
Why?
|
Williams Syndrome | 2 | 2018 | 194 | 0.250 |
Why?
|
Optic Disk | 2 | 2024 | 421 | 0.250 |
Why?
|
Follicle Stimulating Hormone | 4 | 2014 | 726 | 0.250 |
Why?
|
Aromatase | 1 | 2005 | 147 | 0.250 |
Why?
|
Infection Control | 4 | 2017 | 981 | 0.250 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2020 | 2020 | 0.250 |
Why?
|
Neovascularization, Pathologic | 6 | 2016 | 2645 | 0.240 |
Why?
|
Brachytherapy | 2 | 2009 | 1223 | 0.240 |
Why?
|
Fasting | 3 | 2021 | 1603 | 0.240 |
Why?
|
Prognosis | 24 | 2024 | 29625 | 0.240 |
Why?
|
Risk Factors | 55 | 2024 | 74206 | 0.240 |
Why?
|
Placebos | 5 | 2024 | 1667 | 0.240 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 803 | 0.230 |
Why?
|
Cholesterol, LDL | 6 | 2020 | 2382 | 0.230 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2023 | 1727 | 0.230 |
Why?
|
Infertility | 2 | 2023 | 654 | 0.230 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4026 | 0.230 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2014 | 487 | 0.230 |
Why?
|
Prevalence | 23 | 2020 | 15732 | 0.230 |
Why?
|
Tomography, X-Ray Computed | 20 | 2024 | 20570 | 0.230 |
Why?
|
Hyperthyroidism | 2 | 2023 | 294 | 0.220 |
Why?
|
Enterococcus | 2 | 2017 | 159 | 0.220 |
Why?
|
Hospitals, General | 3 | 2017 | 798 | 0.220 |
Why?
|
Adenocarcinoma | 4 | 2020 | 6346 | 0.220 |
Why?
|
Visual Field Tests | 2 | 2024 | 411 | 0.220 |
Why?
|
Cystic Fibrosis | 2 | 2023 | 1285 | 0.220 |
Why?
|
Lipid Metabolism | 5 | 2018 | 1902 | 0.220 |
Why?
|
Parathyroid Hormone | 3 | 2008 | 1803 | 0.220 |
Why?
|
Models, Cardiovascular | 3 | 2021 | 981 | 0.220 |
Why?
|
Drug Therapy, Combination | 14 | 2020 | 6310 | 0.220 |
Why?
|
Subarachnoid Hemorrhage | 2 | 2021 | 1033 | 0.220 |
Why?
|
Antineoplastic Agents, Hormonal | 6 | 2019 | 1520 | 0.210 |
Why?
|
Sex Characteristics | 4 | 2024 | 2639 | 0.210 |
Why?
|
Graft Occlusion, Vascular | 2 | 2017 | 537 | 0.210 |
Why?
|
Opiate Alkaloids | 1 | 2023 | 28 | 0.210 |
Why?
|
Ghrelin | 2 | 2022 | 252 | 0.210 |
Why?
|
Fibrosis | 11 | 2017 | 2049 | 0.210 |
Why?
|
Visual Fields | 2 | 2024 | 1062 | 0.210 |
Why?
|
Obesity, Morbid | 2 | 2024 | 1277 | 0.210 |
Why?
|
Amino Acids, Branched-Chain | 2 | 2023 | 269 | 0.210 |
Why?
|
Pituitary Diseases | 1 | 2023 | 135 | 0.210 |
Why?
|
Insulin-Like Growth Factor I | 7 | 2021 | 1934 | 0.200 |
Why?
|
Bariatric Surgery | 2 | 2024 | 992 | 0.200 |
Why?
|
Insulin Resistance | 5 | 2023 | 3963 | 0.200 |
Why?
|
Bacteriological Techniques | 2 | 2014 | 275 | 0.200 |
Why?
|
Serpins | 1 | 2024 | 247 | 0.200 |
Why?
|
Registries | 19 | 2020 | 8224 | 0.200 |
Why?
|
Subcutaneous Fat | 3 | 2017 | 393 | 0.200 |
Why?
|
Obesity | 10 | 2023 | 12947 | 0.200 |
Why?
|
Intraocular Pressure | 3 | 2024 | 1294 | 0.200 |
Why?
|
Social Problems | 1 | 2002 | 109 | 0.200 |
Why?
|
Aging | 7 | 2020 | 8708 | 0.200 |
Why?
|
Aged, 80 and over | 40 | 2024 | 58976 | 0.200 |
Why?
|
Inflammation | 13 | 2024 | 10773 | 0.190 |
Why?
|
Gastrectomy | 5 | 2024 | 672 | 0.190 |
Why?
|
Prospective Studies | 34 | 2024 | 54425 | 0.190 |
Why?
|
Myocardial Revascularization | 5 | 2020 | 790 | 0.190 |
Why?
|
Anticholesteremic Agents | 3 | 2018 | 966 | 0.190 |
Why?
|
Marketing | 1 | 2003 | 220 | 0.190 |
Why?
|
Aromatase Inhibitors | 5 | 2019 | 513 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 66 | 0.190 |
Why?
|
Hypogonadism | 5 | 2009 | 798 | 0.190 |
Why?
|
Hypolipidemic Agents | 2 | 2015 | 609 | 0.190 |
Why?
|
Angiotensins | 2 | 2022 | 143 | 0.190 |
Why?
|
Massachusetts | 14 | 2021 | 8830 | 0.190 |
Why?
|
Blood Glucose | 9 | 2021 | 6391 | 0.190 |
Why?
|
Angina Pectoris | 3 | 2015 | 959 | 0.180 |
Why?
|
Leuprolide | 3 | 2008 | 312 | 0.180 |
Why?
|
Imaging, Three-Dimensional | 5 | 2024 | 4063 | 0.180 |
Why?
|
Diabetes Mellitus | 4 | 2023 | 5840 | 0.180 |
Why?
|
Reproducibility of Results | 23 | 2024 | 20098 | 0.180 |
Why?
|
Double-Blind Method | 16 | 2024 | 12341 | 0.180 |
Why?
|
Growth Hormone | 3 | 2020 | 569 | 0.180 |
Why?
|
Heparin | 2 | 2021 | 1634 | 0.180 |
Why?
|
Infertility, Male | 1 | 2023 | 395 | 0.180 |
Why?
|
Ethanol | 3 | 2009 | 1324 | 0.180 |
Why?
|
Thyrotropin | 3 | 2023 | 834 | 0.180 |
Why?
|
Dwarfism, Pituitary | 1 | 2020 | 39 | 0.180 |
Why?
|
Bone Marrow | 2 | 2021 | 2911 | 0.180 |
Why?
|
Chi-Square Distribution | 10 | 2017 | 3416 | 0.180 |
Why?
|
Pelvic Bones | 1 | 2022 | 270 | 0.180 |
Why?
|
Peptide Fragments | 6 | 2019 | 5112 | 0.180 |
Why?
|
Blood Donors | 6 | 2011 | 345 | 0.180 |
Why?
|
Fatty Liver | 2 | 2018 | 790 | 0.180 |
Why?
|
Adaptation, Physiological | 2 | 2018 | 1301 | 0.170 |
Why?
|
Nitriles | 4 | 2009 | 971 | 0.170 |
Why?
|
Tracheal Neoplasms | 1 | 2021 | 123 | 0.170 |
Why?
|
Intra-Abdominal Fat | 4 | 2014 | 613 | 0.170 |
Why?
|
Quality of Life | 15 | 2022 | 13367 | 0.170 |
Why?
|
Cannabidiol | 1 | 2022 | 118 | 0.170 |
Why?
|
Blood Circulation | 1 | 2021 | 248 | 0.170 |
Why?
|
Aspirin | 3 | 2017 | 3133 | 0.170 |
Why?
|
Spironolactone | 1 | 2023 | 412 | 0.170 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2021 | 208 | 0.170 |
Why?
|
Tunica Intima | 3 | 2013 | 459 | 0.170 |
Why?
|
Procollagen | 5 | 2016 | 187 | 0.170 |
Why?
|
Automobile Driving | 2 | 2009 | 441 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2020 | 10766 | 0.170 |
Why?
|
Hematoma, Subdural | 1 | 2020 | 127 | 0.170 |
Why?
|
Smoking | 6 | 2015 | 9053 | 0.160 |
Why?
|
Proteomics | 4 | 2024 | 3849 | 0.160 |
Why?
|
No-Reflow Phenomenon | 2 | 2016 | 16 | 0.160 |
Why?
|
Fallopian Tube Neoplasms | 5 | 2009 | 328 | 0.160 |
Why?
|
Proteome | 2 | 2020 | 1862 | 0.160 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2020 | 118 | 0.160 |
Why?
|
Child Development Disorders, Pervasive | 2 | 2015 | 600 | 0.160 |
Why?
|
Organizational Policy | 2 | 2017 | 432 | 0.160 |
Why?
|
Kidney Calculi | 2 | 2014 | 463 | 0.160 |
Why?
|
Puberty | 3 | 2013 | 501 | 0.160 |
Why?
|
Longitudinal Studies | 13 | 2023 | 14605 | 0.160 |
Why?
|
Odds Ratio | 13 | 2021 | 9646 | 0.160 |
Why?
|
Self-Examination | 1 | 1999 | 71 | 0.160 |
Why?
|
Case-Control Studies | 20 | 2020 | 22176 | 0.160 |
Why?
|
Tracheal Stenosis | 1 | 2021 | 228 | 0.160 |
Why?
|
Septal Occluder Device | 1 | 2019 | 125 | 0.160 |
Why?
|
Spine | 2 | 2023 | 1118 | 0.160 |
Why?
|
Menstrual Cycle | 2 | 2020 | 539 | 0.160 |
Why?
|
Hepatitis B | 4 | 2005 | 705 | 0.160 |
Why?
|
Prostatic Neoplasms | 8 | 2012 | 11118 | 0.150 |
Why?
|
Risk-Taking | 3 | 2002 | 1038 | 0.150 |
Why?
|
Hepatitis B Vaccines | 3 | 2005 | 178 | 0.150 |
Why?
|
Food, Fortified | 2 | 2018 | 190 | 0.150 |
Why?
|
Life Change Events | 2 | 2001 | 952 | 0.150 |
Why?
|
Estrogens | 2 | 2019 | 1522 | 0.150 |
Why?
|
Collagen Type I | 6 | 2016 | 616 | 0.150 |
Why?
|
Adipose Tissue, Brown | 2 | 2016 | 764 | 0.150 |
Why?
|
Graft Rejection | 3 | 2023 | 4445 | 0.150 |
Why?
|
Antithrombins | 1 | 2021 | 294 | 0.150 |
Why?
|
Luteinizing Hormone | 3 | 2010 | 820 | 0.150 |
Why?
|
Phacoemulsification | 1 | 2019 | 149 | 0.150 |
Why?
|
Aortic Valve | 2 | 2020 | 1955 | 0.150 |
Why?
|
Neoplastic Stem Cells | 2 | 2017 | 1347 | 0.150 |
Why?
|
Diphosphonates | 2 | 2017 | 636 | 0.150 |
Why?
|
Menstruation | 2 | 2017 | 307 | 0.150 |
Why?
|
Vulvar Neoplasms | 1 | 2020 | 263 | 0.150 |
Why?
|
Hemodynamics | 4 | 2022 | 4159 | 0.150 |
Why?
|
Carboplatin | 7 | 2022 | 794 | 0.150 |
Why?
|
Glaucoma, Angle-Closure | 1 | 2019 | 191 | 0.150 |
Why?
|
Lacrimal Apparatus Diseases | 1 | 2018 | 72 | 0.150 |
Why?
|
Androgens | 4 | 2019 | 1286 | 0.150 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15842 | 0.150 |
Why?
|
Models, Genetic | 4 | 1997 | 3442 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 218 | 0.140 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 407 | 0.140 |
Why?
|
Dyslipidemias | 2 | 2020 | 868 | 0.140 |
Why?
|
Disease-Free Survival | 11 | 2018 | 6814 | 0.140 |
Why?
|
Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
Phenotype | 8 | 2024 | 16591 | 0.140 |
Why?
|
Anti-Bacterial Agents | 5 | 2018 | 7407 | 0.140 |
Why?
|
Vancomycin | 2 | 2018 | 503 | 0.140 |
Why?
|
Thrombectomy | 3 | 2017 | 705 | 0.140 |
Why?
|
Methicillin | 1 | 2017 | 62 | 0.140 |
Why?
|
Probiotics | 1 | 2021 | 378 | 0.140 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6075 | 0.140 |
Why?
|
Adipokines | 2 | 2010 | 310 | 0.140 |
Why?
|
Microscopy | 1 | 2022 | 903 | 0.140 |
Why?
|
Thyroid Function Tests | 1 | 2018 | 288 | 0.140 |
Why?
|
Seasons | 3 | 2020 | 1520 | 0.140 |
Why?
|
Tracheostomy | 1 | 2021 | 426 | 0.140 |
Why?
|
Imidazoles | 2 | 2017 | 1180 | 0.140 |
Why?
|
Cross-Sectional Studies | 20 | 2023 | 26125 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
Bone Development | 2 | 2013 | 472 | 0.140 |
Why?
|
Financing, Personal | 1 | 2019 | 309 | 0.140 |
Why?
|
Veins | 1 | 2021 | 768 | 0.130 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2024 | 895 | 0.130 |
Why?
|
Hepatectomy | 1 | 2020 | 557 | 0.130 |
Why?
|
Disability Evaluation | 3 | 2020 | 1835 | 0.130 |
Why?
|
Eye Neoplasms | 1 | 2018 | 307 | 0.130 |
Why?
|
Quinolines | 2 | 2018 | 764 | 0.130 |
Why?
|
Neural Tube Defects | 1 | 2018 | 255 | 0.130 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 2016 | 48 | 0.130 |
Why?
|
Phosphates | 3 | 2009 | 770 | 0.130 |
Why?
|
Angioscopy | 1 | 2015 | 47 | 0.130 |
Why?
|
Pituitary Gland | 2 | 2010 | 635 | 0.130 |
Why?
|
Sex Factors | 12 | 2024 | 10552 | 0.130 |
Why?
|
Housing | 1 | 2001 | 670 | 0.130 |
Why?
|
Polyglactin 910 | 1 | 2016 | 55 | 0.130 |
Why?
|
Hepatitis B Core Antigens | 3 | 2005 | 90 | 0.130 |
Why?
|
Vascular Resistance | 1 | 2019 | 930 | 0.130 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2018 | 262 | 0.130 |
Why?
|
Folic Acid | 2 | 2018 | 1323 | 0.130 |
Why?
|
Atrial Appendage | 1 | 2019 | 283 | 0.130 |
Why?
|
Fibromyalgia | 1 | 2020 | 405 | 0.130 |
Why?
|
Liver | 4 | 2019 | 7529 | 0.130 |
Why?
|
Neurologic Examination | 1 | 1999 | 916 | 0.130 |
Why?
|
Peritoneal Neoplasms | 5 | 2009 | 711 | 0.130 |
Why?
|
Troponin T | 2 | 2011 | 780 | 0.130 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2013 | 1725 | 0.130 |
Why?
|
Keratinocytes | 1 | 2019 | 790 | 0.130 |
Why?
|
Reproduction | 1 | 2020 | 645 | 0.130 |
Why?
|
Risk Assessment | 21 | 2021 | 23995 | 0.120 |
Why?
|
Cataract Extraction | 1 | 2019 | 467 | 0.120 |
Why?
|
Homocysteine | 3 | 2022 | 638 | 0.120 |
Why?
|
Neoplasms | 6 | 2022 | 22170 | 0.120 |
Why?
|
Multivariate Analysis | 14 | 2016 | 12059 | 0.120 |
Why?
|
Hepatitis B Antibodies | 3 | 2005 | 155 | 0.120 |
Why?
|
Thrombosis | 3 | 2020 | 2942 | 0.120 |
Why?
|
Graft Survival | 3 | 2023 | 3819 | 0.120 |
Why?
|
Cortical Spreading Depression | 1 | 2019 | 288 | 0.120 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2018 | 354 | 0.120 |
Why?
|
Blood Proteins | 1 | 2020 | 1173 | 0.120 |
Why?
|
Lumbar Vertebrae | 4 | 2024 | 1879 | 0.120 |
Why?
|
Verbal Learning | 1 | 2017 | 463 | 0.120 |
Why?
|
Phthalazines | 2 | 2014 | 383 | 0.120 |
Why?
|
Quinazolines | 4 | 2022 | 1371 | 0.120 |
Why?
|
Lymphocyte Subsets | 2 | 1993 | 310 | 0.120 |
Why?
|
Multiple Sclerosis | 3 | 2013 | 3220 | 0.120 |
Why?
|
Anti-Inflammatory Agents | 2 | 2016 | 1809 | 0.120 |
Why?
|
Serum | 1 | 2016 | 209 | 0.120 |
Why?
|
Paclitaxel | 8 | 2022 | 1732 | 0.120 |
Why?
|
Penicillins | 1 | 2018 | 402 | 0.120 |
Why?
|
United States | 27 | 2020 | 72334 | 0.120 |
Why?
|
Administration, Cutaneous | 5 | 2020 | 713 | 0.120 |
Why?
|
Disease Progression | 7 | 2024 | 13506 | 0.120 |
Why?
|
Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2014 | 14 | 0.120 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2012 | 1651 | 0.120 |
Why?
|
Single-Blind Method | 5 | 2017 | 1572 | 0.120 |
Why?
|
Endometrial Neoplasms | 4 | 2013 | 1366 | 0.120 |
Why?
|
Monocytes | 1 | 2023 | 2570 | 0.120 |
Why?
|
Ankle Injuries | 1 | 2018 | 339 | 0.120 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8002 | 0.110 |
Why?
|
Cerebral Cortex | 3 | 2019 | 5777 | 0.110 |
Why?
|
Administration, Oral | 7 | 2019 | 4021 | 0.110 |
Why?
|
Stress, Mechanical | 4 | 2022 | 1674 | 0.110 |
Why?
|
Hip Fractures | 1 | 2022 | 988 | 0.110 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2015 | 393 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 2019 | 560 | 0.110 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2020 | 2751 | 0.110 |
Why?
|
Nephrocalcinosis | 1 | 2014 | 52 | 0.110 |
Why?
|
Androgen Antagonists | 3 | 2008 | 1410 | 0.110 |
Why?
|
Hydrodynamics | 3 | 2021 | 168 | 0.110 |
Why?
|
Antipsychotic Agents | 4 | 2019 | 3067 | 0.110 |
Why?
|
Immunoglobulin G | 3 | 2023 | 4544 | 0.110 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2019 | 740 | 0.110 |
Why?
|
Triazoles | 2 | 2009 | 903 | 0.110 |
Why?
|
Triage | 2 | 2012 | 986 | 0.110 |
Why?
|
Neoplasm Staging | 10 | 2023 | 11121 | 0.110 |
Why?
|
Acupuncture Therapy | 2 | 2009 | 486 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 942 | 0.110 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 1141 | 0.110 |
Why?
|
Psoriasis | 2 | 2012 | 950 | 0.110 |
Why?
|
Body Mass Index | 11 | 2024 | 12953 | 0.110 |
Why?
|
Image Interpretation, Computer-Assisted | 5 | 2017 | 3357 | 0.110 |
Why?
|
Age Factors | 15 | 2020 | 18395 | 0.110 |
Why?
|
Anilides | 2 | 2008 | 411 | 0.110 |
Why?
|
Sialoglycoproteins | 2 | 2004 | 315 | 0.110 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5368 | 0.110 |
Why?
|
Patient Transfer | 2 | 2017 | 794 | 0.110 |
Why?
|
Travel | 1 | 2019 | 796 | 0.110 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2012 | 25 | 0.110 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1329 | 0.110 |
Why?
|
Weight Loss | 1 | 2024 | 2684 | 0.110 |
Why?
|
Sentinel Surveillance | 1 | 2015 | 291 | 0.110 |
Why?
|
Body Weight | 4 | 2018 | 4618 | 0.100 |
Why?
|
Cohort Studies | 16 | 2024 | 41487 | 0.100 |
Why?
|
Executive Function | 2 | 2022 | 1389 | 0.100 |
Why?
|
Adenosine | 1 | 2017 | 808 | 0.100 |
Why?
|
Fractures, Stress | 1 | 2015 | 202 | 0.100 |
Why?
|
Lipoproteins, LDL | 1 | 2016 | 642 | 0.100 |
Why?
|
Cerebral Hemorrhage | 1 | 2024 | 2656 | 0.100 |
Why?
|
Ventricular Fibrillation | 1 | 2015 | 537 | 0.100 |
Why?
|
Visual Cortex | 1 | 2020 | 1107 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 636 | 0.100 |
Why?
|
Feedback, Physiological | 3 | 2010 | 476 | 0.100 |
Why?
|
Mental Recall | 2 | 2017 | 1214 | 0.100 |
Why?
|
Mass Spectrometry | 2 | 2017 | 2192 | 0.100 |
Why?
|
Patient Participation | 2 | 2019 | 1444 | 0.100 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2013 | 76 | 0.100 |
Why?
|
Blood Coagulation Disorders | 2 | 1993 | 350 | 0.100 |
Why?
|
Residence Characteristics | 1 | 2002 | 2093 | 0.100 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 1995 | 2199 | 0.100 |
Why?
|
Angina, Unstable | 1 | 2016 | 888 | 0.100 |
Why?
|
Oligopeptides | 1 | 2018 | 1187 | 0.100 |
Why?
|
Algorithms | 7 | 2020 | 14031 | 0.100 |
Why?
|
Combined Modality Therapy | 10 | 2021 | 8529 | 0.100 |
Why?
|
Uterine Neoplasms | 3 | 2008 | 1420 | 0.100 |
Why?
|
Heart Injuries | 1 | 2014 | 206 | 0.100 |
Why?
|
Incidence | 12 | 2020 | 21353 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 8 | 2017 | 6484 | 0.100 |
Why?
|
Finite Element Analysis | 4 | 2015 | 438 | 0.100 |
Why?
|
Menopause | 1 | 2020 | 1646 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2019 | 1590 | 0.100 |
Why?
|
Education | 1 | 2015 | 537 | 0.100 |
Why?
|
Catheter-Related Infections | 1 | 2015 | 273 | 0.100 |
Why?
|
Hypertension | 3 | 2022 | 8540 | 0.100 |
Why?
|
Vancomycin Resistance | 1 | 2012 | 125 | 0.100 |
Why?
|
Immunosuppressive Agents | 4 | 2019 | 4174 | 0.100 |
Why?
|
Arthroscopy | 1 | 2018 | 969 | 0.100 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2011 | 35 | 0.100 |
Why?
|
Gonadotropins | 2 | 2010 | 241 | 0.100 |
Why?
|
Hip | 1 | 2013 | 255 | 0.100 |
Why?
|
Metabolome | 1 | 2018 | 989 | 0.090 |
Why?
|
Hospital Administration | 1 | 2015 | 353 | 0.090 |
Why?
|
Arginine Vasopressin | 1 | 2011 | 125 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1303 | 0.090 |
Why?
|
Thermogenesis | 1 | 2015 | 475 | 0.090 |
Why?
|
Logistic Models | 9 | 2020 | 13255 | 0.090 |
Why?
|
Joint Instability | 1 | 2018 | 801 | 0.090 |
Why?
|
Alcoholism | 1 | 2002 | 1973 | 0.090 |
Why?
|
HIV | 3 | 2023 | 1582 | 0.090 |
Why?
|
Cardiovascular System | 1 | 2018 | 834 | 0.090 |
Why?
|
Warfarin | 1 | 2019 | 1483 | 0.090 |
Why?
|
Inhibins | 2 | 2009 | 210 | 0.090 |
Why?
|
Cholesterol | 2 | 2023 | 2904 | 0.090 |
Why?
|
Adenoma | 2 | 2011 | 2160 | 0.090 |
Why?
|
CA-125 Antigen | 4 | 2009 | 281 | 0.090 |
Why?
|
HIV-1 | 9 | 2008 | 6863 | 0.090 |
Why?
|
Sensitivity and Specificity | 11 | 2015 | 14666 | 0.090 |
Why?
|
Genetics, Population | 1 | 1996 | 937 | 0.090 |
Why?
|
Amyloid beta-Peptides | 1 | 2024 | 3839 | 0.090 |
Why?
|
Colitis | 1 | 2019 | 1233 | 0.090 |
Why?
|
Survival Rate | 6 | 2021 | 12725 | 0.090 |
Why?
|
Plasma Cells | 1 | 2014 | 599 | 0.090 |
Why?
|
Nasal Mucosa | 1 | 2014 | 416 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 36426 | 0.090 |
Why?
|
Fibronectins | 1 | 2014 | 723 | 0.090 |
Why?
|
Primates | 2 | 2023 | 523 | 0.090 |
Why?
|
Boston | 9 | 2016 | 9326 | 0.090 |
Why?
|
Observer Variation | 5 | 2017 | 2606 | 0.090 |
Why?
|
Cardiovascular Diseases | 5 | 2023 | 15500 | 0.090 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2019 | 1723 | 0.090 |
Why?
|
Tosyl Compounds | 2 | 2008 | 115 | 0.090 |
Why?
|
Neuromuscular Diseases | 1 | 2013 | 258 | 0.090 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 549 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 664 | 0.090 |
Why?
|
Seminiferous Tubules | 1 | 2009 | 25 | 0.090 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 57 | 0.090 |
Why?
|
Social Behavior | 3 | 2009 | 1135 | 0.090 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 91 | 0.090 |
Why?
|
Blood Platelets | 1 | 2021 | 2479 | 0.090 |
Why?
|
Attitude | 1 | 2015 | 775 | 0.090 |
Why?
|
Electrocardiography | 4 | 2019 | 6377 | 0.090 |
Why?
|
Sports | 1 | 2016 | 705 | 0.090 |
Why?
|
Neuroma, Acoustic | 1 | 2014 | 459 | 0.090 |
Why?
|
Glycopeptides | 1 | 2011 | 220 | 0.090 |
Why?
|
Survivors | 3 | 2010 | 2371 | 0.090 |
Why?
|
Child | 21 | 2023 | 80153 | 0.090 |
Why?
|
Hepatitis B virus | 2 | 2003 | 528 | 0.080 |
Why?
|
Pyrazines | 1 | 2015 | 1201 | 0.080 |
Why?
|
Cerebral Infarction | 1 | 2014 | 983 | 0.080 |
Why?
|
Peptides | 6 | 2016 | 4358 | 0.080 |
Why?
|
Attitude to Health | 1 | 1998 | 2025 | 0.080 |
Why?
|
Genomic Imprinting | 1 | 2011 | 329 | 0.080 |
Why?
|
Substance-Related Disorders | 3 | 2023 | 4420 | 0.080 |
Why?
|
Adolescent Development | 1 | 2013 | 282 | 0.080 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 823 | 0.080 |
Why?
|
Metabolomics | 2 | 2018 | 1659 | 0.080 |
Why?
|
Aortic Diseases | 1 | 2015 | 735 | 0.080 |
Why?
|
Japan | 4 | 2020 | 1378 | 0.080 |
Why?
|
Obesity, Abdominal | 1 | 2012 | 374 | 0.080 |
Why?
|
Enterobacteriaceae | 1 | 2010 | 161 | 0.080 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 2072 | 0.080 |
Why?
|
Tonometry, Ocular | 2 | 2024 | 235 | 0.080 |
Why?
|
beta-Lactams | 1 | 2010 | 155 | 0.080 |
Why?
|
Muscle Strength | 1 | 2013 | 624 | 0.080 |
Why?
|
Heart | 2 | 2024 | 4404 | 0.080 |
Why?
|
Drug Resistance | 1 | 2015 | 1596 | 0.080 |
Why?
|
Fibrinogen | 2 | 2022 | 888 | 0.080 |
Why?
|
Radioimmunoassay | 3 | 2010 | 862 | 0.080 |
Why?
|
Infusions, Intravenous | 5 | 2019 | 2219 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 917 | 0.080 |
Why?
|
Donor Selection | 1 | 2011 | 232 | 0.080 |
Why?
|
Neuropsychological Tests | 4 | 2022 | 7045 | 0.080 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9177 | 0.080 |
Why?
|
Prosthesis Failure | 2 | 2014 | 1204 | 0.080 |
Why?
|
Diagnosis, Differential | 8 | 2018 | 12974 | 0.080 |
Why?
|
Receptors, Progesterone | 2 | 2013 | 1129 | 0.080 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1670 | 0.080 |
Why?
|
Cardiac Volume | 1 | 2009 | 197 | 0.080 |
Why?
|
Urinary Calculi | 1 | 2009 | 90 | 0.080 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 802 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7396 | 0.080 |
Why?
|
Gonadal Steroid Hormones | 2 | 2014 | 702 | 0.080 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 188 | 0.080 |
Why?
|
Interviews as Topic | 2 | 2009 | 2696 | 0.080 |
Why?
|
Hyperplasia | 4 | 2013 | 1152 | 0.080 |
Why?
|
Seminiferous Epithelium | 1 | 2008 | 9 | 0.080 |
Why?
|
Atrial Fibrillation | 2 | 2019 | 5127 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 1527 | 0.080 |
Why?
|
Osteocalcin | 2 | 2006 | 274 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2020 | 1613 | 0.080 |
Why?
|
Sick Role | 2 | 1999 | 229 | 0.080 |
Why?
|
Genetic Linkage | 3 | 1998 | 2341 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2010 | 585 | 0.080 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 611 | 0.080 |
Why?
|
HLA Antigens | 2 | 2011 | 1328 | 0.080 |
Why?
|
CD4 Lymphocyte Count | 4 | 2020 | 2571 | 0.080 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 2009 | 361 | 0.070 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2013 | 740 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2529 | 0.070 |
Why?
|
Cushing Syndrome | 1 | 2009 | 241 | 0.070 |
Why?
|
Population Surveillance | 1 | 2018 | 2598 | 0.070 |
Why?
|
Carcinoma, Papillary | 2 | 2011 | 785 | 0.070 |
Why?
|
Terminal Care | 1 | 2020 | 1760 | 0.070 |
Why?
|
Heart Valve Diseases | 1 | 2015 | 1027 | 0.070 |
Why?
|
Pleural Neoplasms | 1 | 2012 | 609 | 0.070 |
Why?
|
Microspheres | 1 | 2011 | 784 | 0.070 |
Why?
|
Aortic Valve Stenosis | 1 | 2020 | 2001 | 0.070 |
Why?
|
ROC Curve | 5 | 2016 | 3579 | 0.070 |
Why?
|
Burkitt Lymphoma | 1 | 2010 | 335 | 0.070 |
Why?
|
HIV Seropositivity | 5 | 2005 | 960 | 0.070 |
Why?
|
Pilot Projects | 6 | 2021 | 8631 | 0.070 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2009 | 217 | 0.070 |
Why?
|
Regression Analysis | 6 | 2013 | 6343 | 0.070 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2008 | 138 | 0.070 |
Why?
|
Osteopathic Medicine | 1 | 2007 | 13 | 0.070 |
Why?
|
Overweight | 1 | 2018 | 2417 | 0.070 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2009 | 478 | 0.070 |
Why?
|
Anticoagulants | 2 | 2021 | 4812 | 0.070 |
Why?
|
Anabolic Agents | 1 | 2010 | 256 | 0.070 |
Why?
|
Injections, Subcutaneous | 3 | 2020 | 681 | 0.070 |
Why?
|
C-Reactive Protein | 4 | 2023 | 3826 | 0.070 |
Why?
|
Prosthesis Design | 4 | 2016 | 2115 | 0.070 |
Why?
|
Area Under Curve | 4 | 2016 | 1638 | 0.070 |
Why?
|
Macaca fascicularis | 2 | 2019 | 903 | 0.070 |
Why?
|
Pelvic Infection | 1 | 2006 | 12 | 0.070 |
Why?
|
Cardiovascular Agents | 1 | 2013 | 840 | 0.070 |
Why?
|
Protein Precursors | 1 | 2011 | 1132 | 0.070 |
Why?
|
Hirudins | 2 | 2021 | 179 | 0.070 |
Why?
|
Immunotherapy | 2 | 2020 | 4652 | 0.070 |
Why?
|
Isoantibodies | 1 | 2011 | 674 | 0.070 |
Why?
|
Aneurysm | 1 | 2010 | 337 | 0.070 |
Why?
|
Osteogenesis | 1 | 2014 | 1273 | 0.070 |
Why?
|
Brain Ischemia | 1 | 2020 | 3049 | 0.070 |
Why?
|
Angioplasty, Balloon | 1 | 2011 | 589 | 0.070 |
Why?
|
Piperazines | 2 | 2014 | 2523 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 12148 | 0.070 |
Why?
|
Phosphorus | 1 | 2008 | 336 | 0.070 |
Why?
|
Psychotropic Drugs | 1 | 2012 | 888 | 0.070 |
Why?
|
Linear Models | 5 | 2017 | 5871 | 0.070 |
Why?
|
California | 5 | 2017 | 1429 | 0.070 |
Why?
|
Cardiomegaly | 1 | 2009 | 590 | 0.070 |
Why?
|
Vision Disorders | 1 | 2014 | 1088 | 0.070 |
Why?
|
Health | 1 | 2009 | 398 | 0.070 |
Why?
|
Emergency Service, Hospital | 4 | 2015 | 7879 | 0.070 |
Why?
|
Tachycardia, Ventricular | 1 | 2015 | 1304 | 0.070 |
Why?
|
Leukopenia | 1 | 2007 | 213 | 0.070 |
Why?
|
Schizophrenia | 6 | 2002 | 6937 | 0.070 |
Why?
|
Stroke Volume | 1 | 2020 | 5496 | 0.070 |
Why?
|
Anti-HIV Agents | 3 | 2020 | 4527 | 0.070 |
Why?
|
Reference Values | 4 | 2018 | 4920 | 0.070 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 891 | 0.070 |
Why?
|
Comorbidity | 7 | 2020 | 10508 | 0.070 |
Why?
|
Bacteremia | 1 | 2013 | 979 | 0.070 |
Why?
|
Postprandial Period | 1 | 2008 | 315 | 0.060 |
Why?
|
Pertussis Vaccine | 1 | 2005 | 39 | 0.060 |
Why?
|
Bordetella pertussis | 1 | 2005 | 45 | 0.060 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2018 | 2518 | 0.060 |
Why?
|
Fluorouracil | 2 | 2023 | 1641 | 0.060 |
Why?
|
Gene Frequency | 1 | 1993 | 3606 | 0.060 |
Why?
|
Femur Neck | 2 | 2024 | 314 | 0.060 |
Why?
|
Wound Healing | 2 | 2015 | 2805 | 0.060 |
Why?
|
Kidney Failure, Chronic | 2 | 2008 | 2471 | 0.060 |
Why?
|
Multiple Birth Offspring | 1 | 2005 | 22 | 0.060 |
Why?
|
Adaptation, Psychological | 3 | 2010 | 2629 | 0.060 |
Why?
|
China | 3 | 2017 | 2369 | 0.060 |
Why?
|
Cocaine-Related Disorders | 1 | 2008 | 461 | 0.060 |
Why?
|
Receptors, Estrogen | 2 | 2013 | 2208 | 0.060 |
Why?
|
Thyroxine | 2 | 2023 | 666 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2017 | 3575 | 0.060 |
Why?
|
Crohn Disease | 2 | 2009 | 2279 | 0.060 |
Why?
|
Abdominal Abscess | 1 | 2006 | 153 | 0.060 |
Why?
|
Acromegaly | 1 | 2008 | 310 | 0.060 |
Why?
|
Diabetes, Gestational | 1 | 2015 | 1248 | 0.060 |
Why?
|
Blood Vessel Prosthesis | 1 | 2010 | 952 | 0.060 |
Why?
|
Whooping Cough | 1 | 2005 | 86 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3204 | 0.060 |
Why?
|
Gene Silencing | 1 | 2011 | 1509 | 0.060 |
Why?
|
Thyroid Gland | 1 | 2011 | 1168 | 0.060 |
Why?
|
Adiponectin | 4 | 2015 | 1113 | 0.060 |
Why?
|
Patient Admission | 1 | 2012 | 1367 | 0.060 |
Why?
|
Acute Lung Injury | 1 | 2008 | 367 | 0.060 |
Why?
|
Thrombolytic Therapy | 1 | 2013 | 2064 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5671 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2319 | 0.060 |
Why?
|
Interleukin-6 | 3 | 2022 | 3208 | 0.060 |
Why?
|
Membrane Proteins | 2 | 2012 | 7856 | 0.060 |
Why?
|
Models, Statistical | 2 | 1997 | 5079 | 0.060 |
Why?
|
Confidence Intervals | 4 | 2014 | 2927 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 12795 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2010 | 988 | 0.060 |
Why?
|
Thyroid Nodule | 1 | 2011 | 764 | 0.060 |
Why?
|
Computer Simulation | 2 | 2014 | 6240 | 0.060 |
Why?
|
Dialysis | 1 | 2004 | 73 | 0.060 |
Why?
|
Metformin | 1 | 2012 | 906 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2020 | 4320 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 885 | 0.060 |
Why?
|
Animals | 13 | 2023 | 168459 | 0.060 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2004 | 132 | 0.060 |
Why?
|
Homocystine | 1 | 2003 | 21 | 0.060 |
Why?
|
Siblings | 1 | 2008 | 825 | 0.060 |
Why?
|
Pedigree | 5 | 2007 | 4542 | 0.060 |
Why?
|
Glucose Tolerance Test | 3 | 2015 | 1178 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2009 | 970 | 0.060 |
Why?
|
Dinoprost | 1 | 2023 | 138 | 0.050 |
Why?
|
Drug Substitution | 2 | 2017 | 290 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 2047 | 0.050 |
Why?
|
Quality of Health Care | 1 | 1998 | 4330 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1405 | 0.050 |
Why?
|
Food Industry | 1 | 2003 | 67 | 0.050 |
Why?
|
Lymphoma, B-Cell | 1 | 2010 | 940 | 0.050 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2017 | 2243 | 0.050 |
Why?
|
Mathematics | 2 | 1996 | 707 | 0.050 |
Why?
|
Emotions | 1 | 2015 | 2739 | 0.050 |
Why?
|
Neisseria meningitidis | 1 | 2003 | 108 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2017 | 8547 | 0.050 |
Why?
|
Leiomyoma | 1 | 2008 | 636 | 0.050 |
Why?
|
Receptor, erbB-2 | 2 | 2013 | 2557 | 0.050 |
Why?
|
Pregnancy | 6 | 2024 | 29874 | 0.050 |
Why?
|
Genes, bcl-2 | 1 | 2023 | 119 | 0.050 |
Why?
|
Viral Load | 3 | 2020 | 3332 | 0.050 |
Why?
|
Endovascular Procedures | 1 | 2017 | 2183 | 0.050 |
Why?
|
Deoxycytidine | 2 | 2006 | 877 | 0.050 |
Why?
|
Agonistic Behavior | 1 | 2002 | 14 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2006 | 754 | 0.050 |
Why?
|
Androstenedione | 1 | 2002 | 131 | 0.050 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2024 | 163 | 0.050 |
Why?
|
Pituitary Neoplasms | 1 | 2011 | 1324 | 0.050 |
Why?
|
Age Determination by Skeleton | 2 | 2013 | 126 | 0.050 |
Why?
|
Meningococcal Vaccines | 1 | 2003 | 94 | 0.050 |
Why?
|
Radiotherapy Dosage | 1 | 2009 | 2898 | 0.050 |
Why?
|
Lower Extremity | 1 | 2011 | 1202 | 0.050 |
Why?
|
Patient Selection | 4 | 2020 | 4244 | 0.050 |
Why?
|
Risk | 4 | 2019 | 9610 | 0.050 |
Why?
|
Blood Transfusion | 2 | 2008 | 1298 | 0.050 |
Why?
|
Self Disclosure | 1 | 2003 | 249 | 0.050 |
Why?
|
Hypothalamus | 1 | 2007 | 999 | 0.050 |
Why?
|
Republic of Korea | 2 | 2015 | 590 | 0.050 |
Why?
|
Social Environment | 2 | 2002 | 1020 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2022 | 141 | 0.050 |
Why?
|
HIV Integrase Inhibitors | 1 | 2024 | 165 | 0.050 |
Why?
|
Calcium | 4 | 2009 | 5722 | 0.050 |
Why?
|
STAT3 Transcription Factor | 1 | 2006 | 871 | 0.050 |
Why?
|
Prothrombin | 1 | 2022 | 191 | 0.050 |
Why?
|
Chimerism | 1 | 2023 | 155 | 0.050 |
Why?
|
Proportional Hazards Models | 6 | 2015 | 12463 | 0.050 |
Why?
|
Dexamethasone | 1 | 2009 | 1948 | 0.050 |
Why?
|
Ischemia | 1 | 2011 | 1882 | 0.050 |
Why?
|
Health Services Accessibility | 2 | 2016 | 5440 | 0.050 |
Why?
|
Poliovirus Vaccine, Inactivated | 1 | 2001 | 24 | 0.050 |
Why?
|
Leucine | 1 | 2023 | 548 | 0.050 |
Why?
|
Genetic Loci | 1 | 2011 | 2632 | 0.050 |
Why?
|
Pirenzepine | 1 | 2002 | 116 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2003 | 234 | 0.050 |
Why?
|
Macrophages | 3 | 2022 | 5769 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2014 | 2244 | 0.050 |
Why?
|
Cholesterol, HDL | 2 | 2022 | 1814 | 0.050 |
Why?
|
Urinary Bladder | 1 | 2008 | 1152 | 0.050 |
Why?
|
Lactobacillus plantarum | 1 | 2021 | 5 | 0.050 |
Why?
|
Age Distribution | 3 | 2015 | 2880 | 0.050 |
Why?
|
Leucovorin | 1 | 2023 | 643 | 0.050 |
Why?
|
Mass Screening | 2 | 2013 | 5428 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2024 | 15631 | 0.050 |
Why?
|
Prone Position | 1 | 2022 | 196 | 0.050 |
Why?
|
Leukocyte Count | 2 | 2020 | 1596 | 0.050 |
Why?
|
Cisplatin | 2 | 2020 | 1651 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2003 | 328 | 0.050 |
Why?
|
Carbohydrates | 1 | 2023 | 390 | 0.050 |
Why?
|
Tunica Media | 2 | 2015 | 112 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3810 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6534 | 0.050 |
Why?
|
Vitamin D | 3 | 2013 | 3303 | 0.050 |
Why?
|
Random Allocation | 2 | 2017 | 2395 | 0.050 |
Why?
|
Rotavirus Vaccines | 1 | 2002 | 62 | 0.050 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2001 | 38 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2023 | 522 | 0.050 |
Why?
|
Insulin | 4 | 2023 | 6596 | 0.050 |
Why?
|
Stroke | 2 | 2019 | 9757 | 0.050 |
Why?
|
Rotavirus Infections | 1 | 2002 | 84 | 0.050 |
Why?
|
Photography | 1 | 2024 | 532 | 0.050 |
Why?
|
Radiography | 4 | 2015 | 6965 | 0.050 |
Why?
|
Ovariectomy | 2 | 2019 | 614 | 0.050 |
Why?
|
Hysterectomy | 1 | 2006 | 857 | 0.050 |
Why?
|
Intussusception | 1 | 2002 | 115 | 0.050 |
Why?
|
Rotarod Performance Test | 1 | 2020 | 63 | 0.050 |
Why?
|
Probability | 2 | 1997 | 2477 | 0.050 |
Why?
|
Drainage | 1 | 2006 | 1157 | 0.050 |
Why?
|
Deltaretrovirus Infections | 2 | 1991 | 25 | 0.050 |
Why?
|
Microcirculation | 2 | 2016 | 1273 | 0.040 |
Why?
|
Viremia | 1 | 2003 | 707 | 0.040 |
Why?
|
Weight Gain | 2 | 2023 | 2348 | 0.040 |
Why?
|
Haloperidol | 1 | 2002 | 389 | 0.040 |
Why?
|
Losartan | 1 | 2022 | 265 | 0.040 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2005 | 497 | 0.040 |
Why?
|
Pipecolic Acids | 1 | 2021 | 77 | 0.040 |
Why?
|
Curettage | 1 | 2020 | 74 | 0.040 |
Why?
|
Topotecan | 3 | 2006 | 132 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 9000 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2001 | 277 | 0.040 |
Why?
|
Zimbabwe | 1 | 2020 | 135 | 0.040 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2003 | 406 | 0.040 |
Why?
|
Penile Erection | 1 | 2020 | 100 | 0.040 |
Why?
|
Nasopharynx | 1 | 2003 | 401 | 0.040 |
Why?
|
Socioeconomic Factors | 5 | 2020 | 7827 | 0.040 |
Why?
|
Bile Acids and Salts | 1 | 2022 | 393 | 0.040 |
Why?
|
Life Style | 1 | 2012 | 3917 | 0.040 |
Why?
|
Proteins | 2 | 2014 | 6032 | 0.040 |
Why?
|
Carcinoma | 1 | 2011 | 2330 | 0.040 |
Why?
|
Partial Thromboplastin Time | 1 | 2021 | 204 | 0.040 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2010 | 1428 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6935 | 0.040 |
Why?
|
Prednisone | 1 | 2004 | 1563 | 0.040 |
Why?
|
Data Collection | 3 | 2012 | 3322 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2020 | 1897 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1405 | 0.040 |
Why?
|
Leiomyosarcoma | 1 | 2004 | 422 | 0.040 |
Why?
|
Abdominal Fat | 2 | 2014 | 221 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 883 | 0.040 |
Why?
|
Quality Improvement | 1 | 2015 | 3801 | 0.040 |
Why?
|
Recurrence | 4 | 2017 | 8465 | 0.040 |
Why?
|
Likelihood Functions | 2 | 1993 | 992 | 0.040 |
Why?
|
Neurons | 1 | 2019 | 9463 | 0.040 |
Why?
|
Osteoporotic Fractures | 1 | 2024 | 411 | 0.040 |
Why?
|
Dietary Fats | 1 | 2007 | 1995 | 0.040 |
Why?
|
Kidney | 3 | 2023 | 7048 | 0.040 |
Why?
|
Electroencephalography | 3 | 2022 | 6225 | 0.040 |
Why?
|
Acute Disease | 4 | 2012 | 7237 | 0.040 |
Why?
|
Survival Analysis | 4 | 2016 | 10090 | 0.040 |
Why?
|
Pneumococcal Vaccines | 1 | 2003 | 397 | 0.040 |
Why?
|
Peripheral Arterial Disease | 1 | 2011 | 1273 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 616 | 0.040 |
Why?
|
Cognition Disorders | 2 | 2007 | 3979 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2022 | 2898 | 0.040 |
Why?
|
Regional Blood Flow | 2 | 2014 | 1496 | 0.040 |
Why?
|
Gels | 1 | 2020 | 420 | 0.040 |
Why?
|
Infant Mortality | 1 | 2004 | 759 | 0.040 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2021 | 330 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3085 | 0.040 |
Why?
|
Glucose | 2 | 2023 | 4346 | 0.040 |
Why?
|
Drug Interactions | 3 | 2010 | 1416 | 0.040 |
Why?
|
Drug Administration Routes | 1 | 2019 | 150 | 0.040 |
Why?
|
Desogestrel | 1 | 2018 | 17 | 0.040 |
Why?
|
GATA3 Transcription Factor | 1 | 2019 | 152 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2020 | 245 | 0.040 |
Why?
|
Treatment Failure | 2 | 2017 | 2645 | 0.040 |
Why?
|
Sepsis | 1 | 2013 | 2585 | 0.040 |
Why?
|
Infusions, Parenteral | 1 | 2019 | 397 | 0.040 |
Why?
|
Perfusion | 1 | 2023 | 1373 | 0.040 |
Why?
|
Renal Dialysis | 1 | 2008 | 1797 | 0.040 |
Why?
|
Transdermal Patch | 1 | 2018 | 51 | 0.040 |
Why?
|
Maze Learning | 1 | 2020 | 483 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2014 | 21012 | 0.040 |
Why?
|
Edema | 1 | 2022 | 766 | 0.040 |
Why?
|
Colorado | 1 | 1998 | 165 | 0.040 |
Why?
|
Pneumococcal Infections | 1 | 2003 | 501 | 0.040 |
Why?
|
Appetite Stimulants | 1 | 2018 | 14 | 0.040 |
Why?
|
Neurites | 1 | 2020 | 391 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2011 | 2332 | 0.040 |
Why?
|
Patient Compliance | 4 | 2010 | 2690 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2022 | 1039 | 0.040 |
Why?
|
Glucose Clamp Technique | 1 | 2018 | 263 | 0.040 |
Why?
|
Receptors, LHRH | 2 | 2009 | 158 | 0.040 |
Why?
|
Skin Diseases | 1 | 2007 | 1094 | 0.040 |
Why?
|
Ethinyl Estradiol | 1 | 2018 | 113 | 0.040 |
Why?
|
Platelet-Rich Plasma | 1 | 2021 | 178 | 0.040 |
Why?
|
Mullerian Ducts | 1 | 2019 | 203 | 0.040 |
Why?
|
Philadelphia | 1 | 2018 | 266 | 0.040 |
Why?
|
Psychopharmacology | 1 | 2019 | 148 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 2019 | 712 | 0.040 |
Why?
|
Comprehensive Health Care | 1 | 1998 | 123 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5247 | 0.040 |
Why?
|
Streptococcus pneumoniae | 1 | 2003 | 730 | 0.040 |
Why?
|
Doxorubicin | 4 | 2006 | 2224 | 0.040 |
Why?
|
Ischemic Attack, Transient | 1 | 2003 | 882 | 0.040 |
Why?
|
Schizophrenic Psychology | 2 | 2002 | 1647 | 0.040 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.040 |
Why?
|
Mice | 6 | 2022 | 81525 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2021 | 983 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 2018 | 263 | 0.040 |
Why?
|
Collagen | 1 | 2005 | 2638 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2009 | 257 | 0.040 |
Why?
|
Genotype | 4 | 2019 | 12990 | 0.040 |
Why?
|
Internal-External Control | 1 | 1999 | 358 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2021 | 1096 | 0.040 |
Why?
|
Administration, Topical | 1 | 2019 | 704 | 0.030 |
Why?
|
Commerce | 1 | 2002 | 606 | 0.030 |
Why?
|
Down-Regulation | 2 | 2015 | 2919 | 0.030 |
Why?
|
Creatinine | 1 | 2022 | 1899 | 0.030 |
Why?
|
Calcium-Binding Proteins | 2 | 2012 | 1069 | 0.030 |
Why?
|
Colitis, Ulcerative | 1 | 2009 | 1922 | 0.030 |
Why?
|
Major Histocompatibility Complex | 1 | 2019 | 870 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2006 | 1784 | 0.030 |
Why?
|
Genetic Markers | 3 | 2016 | 2601 | 0.030 |
Why?
|
Clozapine | 1 | 2000 | 504 | 0.030 |
Why?
|
Leptin | 2 | 2018 | 1597 | 0.030 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 1997 | 247 | 0.030 |
Why?
|
Cell Line, Tumor | 4 | 2017 | 16981 | 0.030 |
Why?
|
Europe | 2 | 2020 | 3422 | 0.030 |
Why?
|
Vitamin B Complex | 1 | 2018 | 299 | 0.030 |
Why?
|
Microvessels | 1 | 2020 | 577 | 0.030 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 1999 | 254 | 0.030 |
Why?
|
Subcellular Fractions | 1 | 2017 | 532 | 0.030 |
Why?
|
Echocardiography, Doppler | 1 | 2020 | 897 | 0.030 |
Why?
|
Creatine Kinase, MB Form | 1 | 2016 | 202 | 0.030 |
Why?
|
Reoperation | 2 | 2021 | 4303 | 0.030 |
Why?
|
Antineoplastic Agents | 3 | 2010 | 13639 | 0.030 |
Why?
|
Caloric Restriction | 1 | 2018 | 299 | 0.030 |
Why?
|
Asia | 1 | 2017 | 619 | 0.030 |
Why?
|
Venous Thromboembolism | 1 | 2009 | 1866 | 0.030 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 1988 | 0.030 |
Why?
|
Universal Precautions | 1 | 2015 | 34 | 0.030 |
Why?
|
Antioxidants | 1 | 2023 | 1668 | 0.030 |
Why?
|
Iron | 1 | 2024 | 1793 | 0.030 |
Why?
|
Gastric Emptying | 1 | 2018 | 242 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2017 | 350 | 0.030 |
Why?
|
Elastic Tissue | 1 | 2015 | 66 | 0.030 |
Why?
|
Suction | 1 | 2016 | 266 | 0.030 |
Why?
|
Drive | 1 | 2015 | 34 | 0.030 |
Why?
|
Immunoassay | 2 | 2011 | 745 | 0.030 |
Why?
|
Drug Repositioning | 1 | 2017 | 233 | 0.030 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2018 | 540 | 0.030 |
Why?
|
Upper Extremity | 1 | 2020 | 657 | 0.030 |
Why?
|
Psychometrics | 2 | 2010 | 3065 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2103 | 0.030 |
Why?
|
Basal Metabolism | 1 | 2016 | 161 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2024 | 2010 | 0.030 |
Why?
|
Drug Combinations | 2 | 2013 | 2048 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2009 | 357 | 0.030 |
Why?
|
Program Evaluation | 2 | 2019 | 2495 | 0.030 |
Why?
|
Copper | 1 | 2017 | 369 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5492 | 0.030 |
Why?
|
Cognition | 2 | 2022 | 6990 | 0.030 |
Why?
|
Methicillin Resistance | 1 | 2015 | 198 | 0.030 |
Why?
|
Nuclear Family | 1 | 1996 | 311 | 0.030 |
Why?
|
Exercise | 2 | 2013 | 5890 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.030 |
Why?
|
Placenta | 1 | 2024 | 1709 | 0.030 |
Why?
|
Hydrocortisone | 2 | 2015 | 1819 | 0.030 |
Why?
|
Infant | 6 | 2023 | 36192 | 0.030 |
Why?
|
Feces | 1 | 2021 | 1497 | 0.030 |
Why?
|
Adipogenesis | 1 | 2017 | 368 | 0.030 |
Why?
|
Extracellular Matrix Proteins | 2 | 2009 | 829 | 0.030 |
Why?
|
Antidepressive Agents | 2 | 2019 | 2897 | 0.030 |
Why?
|
Myocardial Ischemia | 2 | 2017 | 2113 | 0.030 |
Why?
|
Membranes, Artificial | 1 | 2016 | 366 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1175 | 0.030 |
Why?
|
Intensive Care Units | 2 | 2020 | 3745 | 0.030 |
Why?
|
Gonads | 1 | 2014 | 109 | 0.030 |
Why?
|
Hospitals, University | 1 | 2016 | 563 | 0.030 |
Why?
|
Dilatation, Pathologic | 1 | 2015 | 527 | 0.030 |
Why?
|
Deltaretrovirus Antibodies | 2 | 1991 | 9 | 0.030 |
Why?
|
Specialization | 1 | 1998 | 778 | 0.030 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2014 | 186 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 964 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1089 | 0.030 |
Why?
|
Terminology as Topic | 2 | 2011 | 1530 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7967 | 0.030 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 1999 | 556 | 0.030 |
Why?
|
Social Class | 1 | 2002 | 2004 | 0.030 |
Why?
|
Anthropometry | 2 | 2010 | 1349 | 0.030 |
Why?
|
Child, Preschool | 6 | 2021 | 42230 | 0.030 |
Why?
|
Testis | 2 | 2009 | 794 | 0.030 |
Why?
|
Chemical Phenomena | 1 | 2013 | 507 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 148 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 191 | 0.030 |
Why?
|
Exfoliation Syndrome | 1 | 2014 | 113 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2019 | 962 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2057 | 0.030 |
Why?
|
Hospitals | 2 | 2020 | 3882 | 0.030 |
Why?
|
Focus Groups | 1 | 1998 | 1413 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2023 | 3113 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2020 | 1878 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2827 | 0.030 |
Why?
|
Osteopontin | 2 | 2004 | 301 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1886 | 0.030 |
Why?
|
Models, Animal | 1 | 2019 | 2112 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1616 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2006 | 629 | 0.030 |
Why?
|
Porosity | 1 | 2013 | 349 | 0.030 |
Why?
|
Hemophilia A | 2 | 1995 | 360 | 0.020 |
Why?
|
Australia | 1 | 2015 | 1250 | 0.020 |
Why?
|
Rupture | 1 | 2013 | 443 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2014 | 778 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 2014 | 479 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2019 | 1961 | 0.020 |
Why?
|
Diarrhea | 2 | 2013 | 1318 | 0.020 |
Why?
|
Nose | 1 | 2015 | 521 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 2019 | 2693 | 0.020 |
Why?
|
Diet | 2 | 2007 | 8075 | 0.020 |
Why?
|
Guillain-Barre Syndrome | 1 | 2013 | 127 | 0.020 |
Why?
|
Thinness | 1 | 2015 | 490 | 0.020 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2014 | 507 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2020 | 818 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2295 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2011 | 11076 | 0.020 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2016 | 842 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2628 | 0.020 |
Why?
|
Underachievement | 1 | 1991 | 15 | 0.020 |
Why?
|
Practice Guidelines as Topic | 3 | 2014 | 7390 | 0.020 |
Why?
|
Bipolar Disorder | 2 | 2000 | 5092 | 0.020 |
Why?
|
Quadriplegia | 1 | 2013 | 226 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 983 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2015 | 699 | 0.020 |
Why?
|
Blood Coagulation Factors | 1 | 1993 | 365 | 0.020 |
Why?
|
Spinal Dysraphism | 1 | 2013 | 178 | 0.020 |
Why?
|
Autopsy | 1 | 2014 | 1008 | 0.020 |
Why?
|
Weight-Bearing | 1 | 2013 | 532 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 573 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2023 | 3415 | 0.020 |
Why?
|
Oxygen | 1 | 2022 | 4227 | 0.020 |
Why?
|
Pregnancy Trimester, First | 1 | 2015 | 907 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1611 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 22169 | 0.020 |
Why?
|
Length of Stay | 2 | 2016 | 6425 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 3 | 1998 | 793 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2017 | 1116 | 0.020 |
Why?
|
Women's Health | 1 | 2020 | 2065 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3889 | 0.020 |
Why?
|
Wechsler Scales | 1 | 1991 | 257 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3514 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2004 | 3205 | 0.020 |
Why?
|
Income | 1 | 2019 | 1877 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2281 | 0.020 |
Why?
|
Nausea | 1 | 2013 | 679 | 0.020 |
Why?
|
Medicine | 1 | 1998 | 942 | 0.020 |
Why?
|
Ankle Brachial Index | 1 | 2011 | 163 | 0.020 |
Why?
|
Contrast Media | 2 | 2014 | 5311 | 0.020 |
Why?
|
DAX-1 Orphan Nuclear Receptor | 1 | 2009 | 29 | 0.020 |
Why?
|
Preoperative Care | 1 | 2019 | 2242 | 0.020 |
Why?
|
Triiodothyronine | 1 | 2012 | 493 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2735 | 0.020 |
Why?
|
Adipocytes | 1 | 2017 | 1194 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2012 | 999 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2979 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1827 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1039 | 0.020 |
Why?
|
Outpatients | 1 | 2018 | 1597 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1993 | 547 | 0.020 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2012 | 343 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2020 | 1553 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9318 | 0.020 |
Why?
|
Sexual Partners | 2 | 1991 | 796 | 0.020 |
Why?
|
Equipment Contamination | 1 | 2010 | 182 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2021 | 2576 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3384 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3877 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1936 | 0.020 |
Why?
|
Palliative Care | 1 | 2004 | 3598 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4915 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 4243 | 0.020 |
Why?
|
Alleles | 2 | 2007 | 6863 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2626 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2023 | 26198 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1784 | 0.020 |
Why?
|
New England | 1 | 2012 | 1054 | 0.020 |
Why?
|
Speech Recognition Software | 1 | 2009 | 74 | 0.020 |
Why?
|
Hemorrhage | 1 | 2021 | 3424 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 2957 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2010 | 299 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2015 | 1192 | 0.020 |
Why?
|
Fathers | 1 | 2011 | 376 | 0.020 |
Why?
|
Phototherapy | 1 | 2011 | 368 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Aortography | 1 | 2010 | 421 | 0.020 |
Why?
|
Policy | 1 | 2012 | 508 | 0.020 |
Why?
|
Informed Consent | 1 | 2015 | 1008 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1222 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 407 | 0.020 |
Why?
|
Cerebral Palsy | 1 | 2013 | 474 | 0.020 |
Why?
|
Biological Availability | 1 | 2009 | 390 | 0.020 |
Why?
|
Cold Temperature | 1 | 2012 | 785 | 0.020 |
Why?
|
Karyotyping | 1 | 2010 | 1171 | 0.020 |
Why?
|
Limb Salvage | 1 | 2011 | 481 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2151 | 0.020 |
Why?
|
Ketoconazole | 1 | 2007 | 97 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2009 | 618 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
Vascular Patency | 1 | 2011 | 911 | 0.020 |
Why?
|
Psychological Tests | 1 | 2010 | 640 | 0.020 |
Why?
|
Dermatologic Agents | 1 | 2011 | 313 | 0.020 |
Why?
|
Retreatment | 1 | 2009 | 598 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2016 | 1685 | 0.020 |
Why?
|
Guanine | 1 | 2008 | 279 | 0.020 |
Why?
|
Glutamates | 1 | 2008 | 389 | 0.020 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2018 | 1413 | 0.020 |
Why?
|
Phantoms, Imaging | 1 | 2016 | 2526 | 0.020 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1393 | 0.020 |
Why?
|
Body Constitution | 1 | 2007 | 273 | 0.020 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2008 | 125 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 4 | 2019 | 17904 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 2007 | 384 | 0.020 |
Why?
|
Smoking Cessation | 1 | 1998 | 2056 | 0.020 |
Why?
|
Apolipoprotein E2 | 1 | 2007 | 135 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2009 | 590 | 0.020 |
Why?
|
Puberty, Delayed | 1 | 2007 | 121 | 0.020 |
Why?
|
Skin | 1 | 2020 | 4484 | 0.020 |
Why?
|
Kallmann Syndrome | 1 | 2007 | 139 | 0.020 |
Why?
|
Cyclic AMP | 1 | 2010 | 1463 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2011 | 1118 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2015 | 1958 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9539 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 5774 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2218 | 0.020 |
Why?
|
Drug Utilization | 1 | 2012 | 1188 | 0.020 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2010 | 587 | 0.020 |
Why?
|
Health Resources | 1 | 2012 | 935 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1552 | 0.020 |
Why?
|
Hepatitis A Vaccines | 1 | 2005 | 26 | 0.020 |
Why?
|
Physicians, Family | 1 | 2008 | 350 | 0.020 |
Why?
|
Urethra | 1 | 2008 | 405 | 0.020 |
Why?
|
Dinoprostone | 1 | 2009 | 597 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3201 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 3080 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2010 | 621 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2007 | 9031 | 0.020 |
Why?
|
Chromosome Mapping | 3 | 1998 | 4615 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3323 | 0.020 |
Why?
|
Personality Inventory | 2 | 1999 | 1019 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2006 | 175 | 0.020 |
Why?
|
Nerve Tissue Proteins | 2 | 2009 | 4414 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2915 | 0.020 |
Why?
|
Hormones | 1 | 2009 | 869 | 0.020 |
Why?
|
Antigens, CD | 2 | 1993 | 4003 | 0.020 |
Why?
|
Public Health | 1 | 1998 | 2669 | 0.020 |
Why?
|
Exercise Test | 1 | 2013 | 2127 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3617 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 1870 | 0.020 |
Why?
|
Calcitriol | 1 | 2006 | 296 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 2461 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2014 | 2571 | 0.010 |
Why?
|
Tissue Array Analysis | 1 | 2006 | 550 | 0.010 |
Why?
|
Behavior Control | 1 | 2004 | 47 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2882 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Organ Size | 1 | 2009 | 2254 | 0.010 |
Why?
|
Glomerular Filtration Rate | 1 | 2013 | 2176 | 0.010 |
Why?
|
Steroids | 1 | 2009 | 929 | 0.010 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 293 | 0.010 |
Why?
|
Microbial Sensitivity Tests | 1 | 2010 | 1937 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1993 | 6228 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2078 | 0.010 |
Why?
|
Poverty | 1 | 2016 | 2698 | 0.010 |
Why?
|
Immunization | 1 | 2008 | 1228 | 0.010 |
Why?
|
Prostatectomy | 1 | 2012 | 1824 | 0.010 |
Why?
|
Carotid Arteries | 1 | 2008 | 941 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2510 | 0.010 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2003 | 56 | 0.010 |
Why?
|
Complementary Therapies | 1 | 2008 | 486 | 0.010 |
Why?
|
World Health Organization | 1 | 2010 | 1322 | 0.010 |
Why?
|
Myocardium | 1 | 2016 | 4726 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2014 | 5869 | 0.010 |
Why?
|
Pelvis | 1 | 2008 | 732 | 0.010 |
Why?
|
Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 61 | 0.010 |
Why?
|
Pyridoxal Phosphate | 1 | 2003 | 125 | 0.010 |
Why?
|
Signal Transduction | 1 | 2006 | 23445 | 0.010 |
Why?
|
Rectum | 1 | 2008 | 892 | 0.010 |
Why?
|
Drug Resistance, Bacterial | 1 | 2010 | 1048 | 0.010 |
Why?
|
Heart Atria | 1 | 2009 | 1345 | 0.010 |
Why?
|
Psychology | 1 | 2005 | 356 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2010 | 5305 | 0.010 |
Why?
|
Family Characteristics | 1 | 2008 | 1004 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2015 | 3188 | 0.010 |
Why?
|
Serotyping | 1 | 2003 | 325 | 0.010 |
Why?
|
Gene Dosage | 1 | 2007 | 1217 | 0.010 |
Why?
|
Apolipoprotein E4 | 1 | 2007 | 708 | 0.010 |
Why?
|
Control Groups | 1 | 2002 | 104 | 0.010 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2003 | 294 | 0.010 |
Why?
|
Blood Pressure | 2 | 2008 | 8481 | 0.010 |
Why?
|
Vagina | 1 | 2008 | 838 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1336 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 10209 | 0.010 |
Why?
|
Urban Population | 1 | 2010 | 2036 | 0.010 |
Why?
|
Asthma | 1 | 2001 | 6234 | 0.010 |
Why?
|
Government Programs | 1 | 2004 | 279 | 0.010 |
Why?
|
Health Status | 2 | 2010 | 4077 | 0.010 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 276 | 0.010 |
Why?
|
Primary Health Care | 1 | 1998 | 4686 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2001 | 15936 | 0.010 |
Why?
|
Decision Making | 1 | 2015 | 3929 | 0.010 |
Why?
|
Syndrome | 1 | 2008 | 3267 | 0.010 |
Why?
|
Sperm Count | 1 | 2002 | 229 | 0.010 |
Why?
|
Software | 1 | 1996 | 4434 | 0.010 |
Why?
|
Cryptorchidism | 1 | 2002 | 151 | 0.010 |
Why?
|
Vaccines, Combined | 1 | 2001 | 70 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2015 | 3249 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2004 | 629 | 0.010 |
Why?
|
Affect | 1 | 2009 | 1486 | 0.010 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2004 | 550 | 0.010 |
Why?
|
Curriculum | 1 | 2015 | 3743 | 0.010 |
Why?
|
Primary Prevention | 1 | 2009 | 1186 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18252 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3530 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2006 | 1008 | 0.010 |
Why?
|
Sodium | 1 | 2006 | 1588 | 0.010 |
Why?
|
Age of Onset | 1 | 2008 | 3305 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2004 | 1991 | 0.010 |
Why?
|
Mothers | 1 | 2011 | 2198 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2273 | 0.010 |
Why?
|
Genetic Variation | 1 | 1996 | 6567 | 0.010 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2000 | 109 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2421 | 0.010 |
Why?
|
Family | 1 | 1991 | 3194 | 0.010 |
Why?
|
Heterozygote | 1 | 2007 | 2787 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 2003 | 864 | 0.010 |
Why?
|
Antibodies | 1 | 2008 | 2418 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2003 | 524 | 0.010 |
Why?
|
Serum Albumin | 1 | 2003 | 672 | 0.010 |
Why?
|
Motivation | 1 | 2010 | 2006 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2007 | 1250 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2010 | 2759 | 0.010 |
Why?
|
Energy Intake | 1 | 2007 | 2134 | 0.010 |
Why?
|
Brain | 2 | 2024 | 27112 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2009 | 2180 | 0.010 |
Why?
|
Cytoplasm | 1 | 2004 | 1510 | 0.010 |
Why?
|
Assertiveness | 1 | 1999 | 18 | 0.010 |
Why?
|
Cross-Cultural Comparison | 1 | 2002 | 635 | 0.010 |
Why?
|
Health Maintenance Organizations | 1 | 2002 | 659 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3242 | 0.010 |
Why?
|
Immunization, Secondary | 1 | 2001 | 367 | 0.010 |
Why?
|
Florida | 2 | 1991 | 431 | 0.010 |
Why?
|
Leukocytes | 1 | 2007 | 2026 | 0.010 |
Why?
|
Safety | 1 | 2003 | 1150 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2008 | 2469 | 0.010 |
Why?
|
Epidemiologic Studies | 1 | 2002 | 675 | 0.010 |
Why?
|
Patient Dropouts | 1 | 2000 | 412 | 0.010 |
Why?
|
Critical Illness | 1 | 2011 | 2723 | 0.010 |
Why?
|
Ambulatory Care | 2 | 1999 | 2775 | 0.010 |
Why?
|
Models, Biological | 1 | 2014 | 9469 | 0.010 |
Why?
|
Occipital Lobe | 1 | 1999 | 374 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 1998 | 375 | 0.010 |
Why?
|
Up-Regulation | 1 | 2006 | 4124 | 0.010 |
Why?
|
Medication Adherence | 1 | 2009 | 2176 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2006 | 3429 | 0.010 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 1998 | 350 | 0.010 |
Why?
|
Canada | 1 | 2002 | 2122 | 0.010 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 1998 | 367 | 0.010 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 1998 | 361 | 0.010 |
Why?
|
Limbic System | 1 | 1999 | 419 | 0.010 |
Why?
|
DNA, Viral | 1 | 2003 | 2202 | 0.010 |
Why?
|
Echocardiography | 1 | 2009 | 4989 | 0.010 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 1998 | 452 | 0.010 |
Why?
|
Marijuana Abuse | 1 | 2000 | 411 | 0.010 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1998 | 535 | 0.010 |
Why?
|
Lod Score | 1 | 1997 | 600 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1998 | 783 | 0.010 |
Why?
|
Benzodiazepines | 1 | 2002 | 1132 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3778 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2002 | 2329 | 0.010 |
Why?
|
MicroRNAs | 1 | 2011 | 3816 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8320 | 0.010 |
Why?
|
Epilepsy | 1 | 1991 | 3290 | 0.010 |
Why?
|
Genome, Human | 2 | 1998 | 4425 | 0.010 |
Why?
|
Ultrasonography | 1 | 2008 | 5972 | 0.010 |
Why?
|
Blood Component Transfusion | 1 | 1995 | 142 | 0.010 |
Why?
|
Atrophy | 1 | 1999 | 1633 | 0.010 |
Why?
|
Parietal Lobe | 1 | 1999 | 852 | 0.010 |
Why?
|
Confidentiality | 1 | 1998 | 609 | 0.010 |
Why?
|
Mutation | 2 | 2009 | 30052 | 0.010 |
Why?
|
Cause of Death | 1 | 2004 | 3683 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2005 | 3060 | 0.010 |
Why?
|
Demography | 1 | 1997 | 1648 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2004 | 3673 | 0.010 |
Why?
|
Frontal Lobe | 1 | 1998 | 1420 | 0.010 |
Why?
|
Functional Laterality | 1 | 1998 | 2257 | 0.010 |
Why?
|
Radioimmunoprecipitation Assay | 1 | 1991 | 16 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1997 | 2850 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2004 | 2567 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9486 | 0.010 |
Why?
|
Psychosocial Deprivation | 1 | 1991 | 99 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2008 | 5336 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 1998 | 1881 | 0.010 |
Why?
|
West Indies | 1 | 1989 | 32 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2000 | 6019 | 0.010 |
Why?
|
San Francisco | 1 | 1989 | 162 | 0.010 |
Why?
|
Los Angeles | 1 | 1989 | 243 | 0.010 |
Why?
|
Homosexuality | 1 | 1989 | 267 | 0.000 |
Why?
|
Memory | 1 | 1998 | 2188 | 0.000 |
Why?
|
Health Behavior | 1 | 2000 | 2643 | 0.000 |
Why?
|
Prefrontal Cortex | 1 | 1999 | 2219 | 0.000 |
Why?
|
Attention | 1 | 1998 | 2396 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1991 | 1705 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2003 | 18965 | 0.000 |
Why?
|
Homosexuality, Male | 1 | 1995 | 1334 | 0.000 |
Why?
|
New York City | 1 | 1989 | 731 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1993 | 2358 | 0.000 |
Why?
|
Parent-Child Relations | 1 | 1991 | 761 | 0.000 |
Why?
|
Blotting, Western | 1 | 1991 | 5035 | 0.000 |
Why?
|